| Title: |
Clinical relevance of highly-sensitive Tg assay in monitoring low-risk patients treated for differentiated thyroid cancer on suppressive L-Thyroxine therapy |
| Authors: |
Iervasi G.; Iervasi A.; Ferdeghini M.; Solimeo C.; Bottoni A.; Rossi L.; Colato C.; Zucchelli G. |
| Source: |
Clinical endocrinology (Oxf., Print) 67 (2007): 434–441. ; info:cnr-pdr/source/autori:Iervasi G.; Iervasi A.; Ferdeghini M.; Solimeo C.; Bottoni A.; Rossi L.; Colato C.; Zucchelli G./titolo:Clinical relevance of highly-sensitive Tg assay in monitoring low-risk patients treated for differentiated thyroid cancer on suppressive L-Thyroxine therapy/doi:/rivista:Clinical endocrinology (Oxf., Print)/anno:2007/pagina_da:434/pagina_a:441/intervallo_pagine:434–441/volume:67 |
| Publisher Information: |
Blackwell Scientific Publications., Oxford;, Regno Unito |
| Publication Year: |
2007 |
| Collection: |
PUMAlab (ISTI CNR - Consiglio Nazionale delle Ricerche / National Research Council) |
| Subject Terms: |
Differentiated Thyroid Cancer; Thyroglobulin; Chemiluminescent immunoassay |
| Description: |
Objective: Serum Thyroglobulin (Tg) represents a high specific biomarker for the detection of residual functioning thyroid tissue and/or recurrence/metastases in the follow-up of treated patients for differentiated thyroid cancer (DTC). Recently, several highly sensitive Tg assays have been developed but their clinical benefit still remains undetermined. Design: We evaluated the clinical impact of Tg values measured by a highly sensitive Tg assay (Access, Beckman) during L-Thyroxine (L-T4) suppressive therapy in a group of 106 low-risk DTC-treated patients, submitted to routinely follow-up including Recombinant Human Thyrotropin stimulation (rh-TSH). Main Outcome: Undetectable (i.e. 0.1 mg/L) Tg Access showed a very high negative predictive value (99%) of a Tg negative response (i.e. 2 mg/L) to rh-TSH. Minimal amounts of measurable Tg, (i.e. 0.1 but 1 mg/L) during L-T4 therapy correctly identified the majority of patients (80%) with a positive (2 mg/L) response to rh-TSH. Conclusions: Our results indicate that routinely introduction of a highly-sensitive Tg assay may represent a useful diagnostic tool which helps to better interpret Tg results during monitoring of DTC-treated low-risk patients on L-T4 suppressive therapy and to optimize the execution of the more expensive rh-TSH test. |
| Document Type: |
article in journal/newspaper |
| Language: |
unknown |
| Relation: |
info:cnr-pdr/author/matricola:9161/IERVASI/GIORGIO; info:cnr-pdr/author/matricola:9661/BOTTONI/ANTONIO; info:cnr-pdr/author/matricola:26113/ZUCCHELLI/GIANCARLO; http://www.cnr.it/prodotto/i/23947; https://publications.cnr.it/doc/23947 |
| Availability: |
http://www.cnr.it/prodotto/i/23947; https://publications.cnr.it/doc/23947 |
| Accession Number: |
edsbas.243953BE |
| Database: |
BASE |